0001209191-17-059331.txt : 20171103 0001209191-17-059331.hdr.sgml : 20171103 20171103193058 ACCESSION NUMBER: 0001209191-17-059331 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171102 FILED AS OF DATE: 20171103 DATE AS OF CHANGE: 20171103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Azelby Robert CENTRAL INDEX KEY: 0001656998 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36781 FILM NUMBER: 171177936 MAIL ADDRESS: STREET 1: 307 WESTLAKE AVE. NORTH, STE 300 CITY: SEATTLE STATE: WA ZIP: 98109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Juno Therapeutics, Inc. CENTRAL INDEX KEY: 0001594864 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463656275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 2065821600 MAIL ADDRESS: STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200 CITY: SEATTLE STATE: WA ZIP: 98109 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-11-02 0 0001594864 Juno Therapeutics, Inc. JUNO 0001656998 Azelby Robert C/O 400 DEXTER AVENUE NORTH SUITE 1200 SEATTLE WA 98109 0 1 0 0 EVP & Chief Commercial Officer Common Stock 2017-11-02 4 M 0 6666 25.29 A 79998 D Common Stock 2017-11-02 4 S 0 6666 54.95 D 73332 D Stock Option (Right to Buy) 25.29 2017-11-02 4 M 0 6666 0.00 D 2026-11-07 Common Stock 6666 33334 D The sales and related option exercises reported on this Form 4 were executed pursuant to a trading plan adopted by the reporting person on March 20, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934. 1/48th of the shares subject to the option became vested and exercisable on December 8, 2016 and 1/48th of the shares subject to the option vest monthly thereafter. /s/ Zachary D. Hale, attorney-in-fact 2017-11-03